Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Xenon Pharmaceuticals Inc. (XENE : NSDQ)
 
 • Company Description   
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of medicines through the application of its proprietary discovery platform, which it refer to as Extreme Genetics. Xenon is developing proprietary product candidates for the treatment of both orphan as well as more prevalent diseases. The company offers Glybera (R), a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan disorder. Xenon Pharmaceuticals Inc. is headquartered in Burnaby, Canada.

Number of Employees: 153

 
 • Price / Volume Information   
Yesterday's Closing Price: $29.92 Daily Weekly Monthly
20 Day Moving Average: 467,561 shares
Shares Outstanding: 53.11 (millions)
Market Capitalization: $1,588.92 (millions)
Beta: 1.75
52 Week High: $36.42
52 Week Low: $14.65
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -8.25% 0.53%
12 Week -4.47% 3.65%
Year To Date -4.23% 13.89%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
200 - 3650 GILMORE WAY
-
BURNABY,A1 V5G 4W8
CAN
ph: 604-484-3300
fax: 604-484-3450
investors@xenon-pharma.com http://www.xenon-pharma.com
 
 • General Corporate Information   
Officers
Ian Mortimer - Chief Executive Officer; President and Director
Simon Pimstone - Executive Chairman
Sherry Aulin - Chief Financial Officer
Mohammad Azab - Director
Steven Gannon - Director

Peer Information
Xenon Pharmaceuticals Inc. (CORR.)
Xenon Pharmaceuticals Inc. (RSPI)
Xenon Pharmaceuticals Inc. (CGXP)
Xenon Pharmaceuticals Inc. (BGEN)
Xenon Pharmaceuticals Inc. (GTBP)
Xenon Pharmaceuticals Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 98420N105
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/10/22
Share - Related Items
Shares Outstanding: 53.11
Most Recent Split Date: (:1)
Beta: 1.75
Market Capitalization: $1,588.92 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.47 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.04 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/10/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.93
Price/Cash Flow: -
Price / Sales: 69.55
EPS Growth
vs. Year Ago Period: 16.67%
vs. Previous Quarter: 38.60%
Sales Growth
vs. Year Ago Period: 101.15%
vs. Previous Quarter: 134.57%
ROE
03/31/22 - -20.94
12/31/21 - -24.14
09/30/21 - -28.30
ROA
03/31/22 - -19.75
12/31/21 - -22.41
09/30/21 - -25.63
Current Ratio
03/31/22 - 68.36
12/31/21 - 39.03
09/30/21 - 19.94
Quick Ratio
03/31/22 - 68.36
12/31/21 - 39.03
09/30/21 - 19.94
Operating Margin
03/31/22 - -360.80
12/31/21 - -425.88
09/30/21 - -328.86
Net Margin
03/31/22 - -360.80
12/31/21 - -425.88
09/30/21 - -328.86
Pre-Tax Margin
03/31/22 - -363.84
12/31/21 - -423.13
09/30/21 - -333.22
Book Value
03/31/22 - 10.20
12/31/21 - 10.51
09/30/21 - 5.87
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©